Ment Health Clin. 2016 Nov 3;6(6):277-284. doi: 10.9740/mhc.2016.11.277. eCollection 2016 Nov.
Abstract
Cannabis is being increasingly used as a medical treatment for a variety of illnesses. However, the cannabis plant has more than 70 different phytocannabinoids with potential pharmacologic activity. Two of the most researched phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Evidence suggests CBD can decrease some of the psychomimetic effects of THC. This has led to the development of a new drug, Nabiximols, for the treatment of moderate to severe spasticity due to multiple sclerosis. A discussion of evidence supporting proposed pharmacodynamic interplay between CBD and THC is presented.
KEYWORDS:
Nabiximols; cannabidiol; cannabis; delta-9-tetrahydrocannabinol; marijuana
- PMID: 29955482
- PMCID: PMC6007535
- DOI: 10.9740/mhc.2016.11.277
-
Conflict of interest statement
Disclosures: Dr Ranganathan has received research support from Insys Therapeutics. The other authors have no disclosures to make.